Legend Biotech's CAR-T Generates $369M in Q1; Sanofi's OX40L mAb Amlitelimab Fails Phase II Asthma Trial
Legend Biotech
Tumor Cell Immunotherapy Developer
Sanofi
Pharmaceutical Manufacturer
Johnson & Johnson
Medical Device R&D and Manufacturer
DualityBio
Innovative Molecular Type Drug Developer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Johnson & Johnson Releases Latest Report Card.
On April 15, Johnson & Johnson released its first-quarter financial report. First-quarter sales were $21.89 billion, estimated at $21.58 billion; first-quarter pharmaceutical revenue was $13.87 billion, estimated at $13.43 billion.
According to Johnson & Johnson's financial report, Legend Biotech's CAR-T revenue in the first quarter was $369 million, continuing its strong sales performance.
Sanofi's luck is bad.
On April 15, Sanofi announced that the Phase II TIDE-Asthma study of OX40L monoclonal antibody Amlitelimab for the treatment of asthma did not meet the primary endpoint. The Phase III study plan for this drug in asthma is currently under development.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Capital Information
1) DualityBio Maps Out Hong Kong IPO, Market Value Breaks Through 17.5 Billion HKD
On April 15, the ADC leader was listed on the Hong Kong Stock Exchange, with its stock price closing up 116.7%, and the latest market value reaching HKD 17.514 billion.
/ 02 /
Pharmaceutical News
1) Zedman Pharmaceuticals' TAP-1503 Cream Receives Clinical Approval
On April 15, according to the CDE official website, Zedman Pharmaceuticals' TAP-1503 Cream received clinical approval for the proposed topical treatment of alopecia areata in patients aged 12 years and above.
2) AstraZeneca's Tezepelumab Injection Receives Clinical Approval
On April 15, according to the CDE official website, AstraZeneca's Tezepelumab injection received clinical approval for the treatment of adult patients with moderate to very severe chronic obstructive pulmonary disease (COPD).
/ 03 /
Instrument Tracking
1) JW Medical's Cobalt Chromium Alloy Biodegradable Coating Rapamycin-Eluting Coronary Stent System Receives Registration Approval
On April 15, according to the NMPA website, JW Medical's cobalt-chromium alloy biodegradable coating sirolimus-eluting coronary stent system received registration approval.
/ 04 /
Digital Healthcare Daily
1) Mao Ji, former General Manager of Baidu's Greater Health Business Group Pharmaceutical Enterprise Marketing, has resigned.
Recently, according to media reports, Mao Ji, the former General Manager of Pharmaceutical Enterprise Marketing at Baidu's Greater Health Business Group, has resigned and joined "MedicineNet" as the Chief Commercial Officer. Public information shows that Mao Ji graduated from Shanghai Jiao Tong University and has previously served as the General Manager of Tencent's Internet Health and Pharmaceuticals, General Manager of Pharmaceutical Enterprise Marketing at Baidu's Greater Health Business Group, and Head of the Three Products and One Device Industry.
/ 05 /
Global Pharma News
1) BMS's Mavacamten Phase III Study for Non-Obstructive Hypertrophic Cardiomyopathy Did Not Meet Primary Endpoint
On April 14, BMS announced that the Phase III study of mavacamten, a cardiac myosin inhibitor for the treatment of non-obstructive hypertrophic cardiomyopathy, did not meet its primary endpoint.
2) Sanofi's OX40L Antibody Asthma Phase II Study Did Not Meet Primary Endpoint
On April 15, Sanofi announced that the Phase II TIDE-Asthma study of OX40L monoclonal antibody Amlitelimab for the treatment of asthma did not meet the primary endpoint. The Phase III asthma study plan for this drug is currently in development.
3) Johnson & Johnson's Q1 Sales Reach $21.89 Billion
On April 15, Johnson & Johnson released its first-quarter financial report. First-quarter sales were $21.89 billion, estimated at $21.58 billion; first-quarter pharmaceutical revenue was $13.87 billion, estimated at $13.43 billion. Johnson & Johnson forecasts full-year sales to be between $91 billion and $91.8 billion.
PS: Welcome to scan the QR code below to add the WeChat ID of Anji Jun for communication.